- Home
- ANTX vs BRNS Comparison
ANTX vs BRNS Comparison
Compare ANTX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- BRNS
- Stock Information
- Founded
- ANTX 2017
- BRNS 2016
- Country
- ANTX United States
- BRNS United Kingdom
- Employees
- ANTX N/A
- BRNS N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- BRNS Health Care
- Exchange
- ANTX Nasdaq
- BRNS Nasdaq
- Market Cap
- ANTX 37.6M
- BRNS 43.8M
- IPO Year
- ANTX 2022
- BRNS 2021
- Fundamental
- Price
- ANTX $1.41
- BRNS $1.06
- Analyst Decision
- ANTX Hold
- BRNS Strong Buy
- Analyst Count
- ANTX 5
- BRNS 2
- Target Price
- ANTX $3.50
- BRNS $3.00
- AVG Volume (30 Days)
- ANTX 168.1K
- BRNS 23.0K
- Earning Date
- ANTX 03-27-2025
- BRNS 03-19-2025
- Dividend Yield
- ANTX N/A
- BRNS N/A
- EPS Growth
- ANTX N/A
- BRNS N/A
- EPS
- ANTX N/A
- BRNS N/A
- Revenue
- ANTX N/A
- BRNS $14,969,000.00
- Revenue This Year
- ANTX N/A
- BRNS $1,803.87
- Revenue Next Year
- ANTX N/A
- BRNS N/A
- P/E Ratio
- ANTX N/A
- BRNS N/A
- Revenue Growth
- ANTX N/A
- BRNS 106.21
- 52 Week Low
- ANTX $0.87
- BRNS $0.80
- 52 Week High
- ANTX $3.88
- BRNS $4.16
- Technical
- Relative Strength Index (RSI)
- ANTX 72.16
- BRNS 54.83
- Support Level
- ANTX $1.09
- BRNS $0.93
- Resistance Level
- ANTX $1.39
- BRNS $1.17
- Average True Range (ATR)
- ANTX 0.06
- BRNS 0.11
- MACD
- ANTX 0.03
- BRNS 0.01
- Stochastic Oscillator
- ANTX 94.20
- BRNS 54.17
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.